Non-small cell lung cancer patients who are ineligible for platinum-based chemotherapy benefit from atezolizumab monotherapy.

Published Date: 16 Aug 2023

First-line atezolizumab monotherapy is linked to improved overall survival compared to single-agent chemotherapy in patients with non-small cell lung cancer (NSCLC) who are ineligible for platinum-based chemotherapy.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Telemedicine Not Reaching Rural Psychiatric Patients

2.

Loneliness and social isolation linked to heightened risk of death in those with cancer

3.

Both men and women who receive the HPV vaccine have a lower risk of developing multiple cancer types.

4.

According to a study, breast cancer in Syrian refugees tends to be diagnosed at an earlier stage and with more advanced tumors.

5.

Non-small cell lung cancer patients who are ineligible for platinum-based chemotherapy benefit from atezolizumab monotherapy.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot